Two new studies from the laboratory of Dr. Alex Mazo at the Sidney Kimmel Cancer Center at Thomas Jefferson University, along with collaborators from SKCC, the Vickie and Jack Farber Institute for Neuroscience and other institutions, provide new insights into the structure of chromatin and its implications for cellular differentiation.
The FDA has granted pembrolizumab approvals in the frontline and second-line settings for urothelial carcinoma.
Researchers at Istanbul University Institute of Oncology have concluded that patients with high-risk extremity soft tissue sarcoma have similar 3-year outcomes whether they are assigned to neoadjuvant sequential chemoradiotherapy or radiation alone.
Clara N. Lambert and the Association of Community Cancer Centers have created an online course called Financial Advocacy Boot Camp, which is designed to give experienced and novice financial navigators a review of essential knowledge for finding patient funds.
Ronald S. Go, MD, provides perspective on thrombotic microangiopathy and paroxysmal nocturnal hemoglobinuria, including how community physicians can properly diagnose and treat them.
Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.
The FDA has granted a priority review designation to copanlisib as a treatment for patients with relapsed/refractory follicular lymphoma who have received at 2 least prior therapies, according to Bayer, the manufacturer of the PI3K dual-isoform inhibitor.
Lisa Fucito, PhD, discusses why it is imperative for patients to quit smoking after a head and neck cancer diagnosis.
The FDA has granted a breakthrough therapy designation to entrectinib for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors who have either progressed following prior therapies or who have no acceptable standard therapies.
Prashant Kapoor, MD, discusses the importance of minimal residual disease negativity, using International Myeloma Working Group criteria, and field-changing pivotal data in multiple myeloma.
Mary C. White, ScD, MPH, discusses the unmet needs near and after the stopping age for cervical cancer screening.
As part of the 2016 American Urological Association Census, investigators randomly assigned Maslach Burnout Inventory questions to determine how many urologists met the criteria for burnout.
Aref Al-Kali, MD, discusses some of the recent advancements, exciting ongoing trials, and largest unanswered questions in AML.
The National Cancer Institute has named Winship Cancer Institute at Emory University a Comprehensive Cancer Center.
Ramaswamy Govindan, MD, discusses the rapid therapeutic changes in NSCLC and the sequencing questions physicians are currently asking.
Dennis Scribner, MD, discusses the treatment landscape for patients with recurrent ovarian cancer and how PARP inhibitors have enhanced the treatment options for this population.
Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.
Results from the phase III SABRINA trial showed that subcutaneous administration of rituximab produced nearly identical response rates and toxicity as IV administration in the first-line treatment of follicular lymphoma.
Shaji Kumar, MD, discusses novel therapies for patients with multiple myeloma in detail, the sequencing challenges ahead, and which current agents pose the greatest challenge.
Bradley C. Leibovich, MD, discusses the benefits of surgery and the need for more effective drug treatments for patients with metastatic renal cell carcinoma.
Tim F. Greten, MD, discussed the evolving role of immunotherapy in hepatocellular carcinoma.
Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation for patients with renal cell carcinoma and highlights ongoing trials examining the modality.
Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard care with platinum-based chemotherapy and radiotherapy.
Fahima Dossa, MD, discussed the potential of using a watch-and-wait approach in the management of patients with rectal cancer.
The US Preventive Services Task Force announced that it recommends against screening for thyroid cancer in asymptomatic adults.
High PD-L1 expression is closely associated with local failure following radiotherapy in HPV-negative head and neck squamous cell carcinomas, according to recent study.
Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.
According to findings from part 2 of the phase III COLUMBUS trial, the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of disease progression or death by 23% compared with single-agent encorafenib for patients with BRAF-mutant melanoma.
The FDA has granted an accelerated approval to pembrolizumab for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer, regardless of PD-L1 expression.
Jonathan Strosberg, MD, discusses recent developments and emerging agents in the field of neuroendocrine tumors.